The US Congress proposes a package of bills on drug pricing, including changes to the treatment of reverse payments, product hopping, sham petitions, and patent dancing

What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new package of proposed bills, announced in connection with an April 2021 US House of Representatives Judiciary Antitrust Subcommittee hearing on drug prices, may indicate that federal lawmakers are turning their competition focus to the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • White & Case (New York)
  • White & Case (New York)
  • White & Case (New York)
  • White & Case (Washington)
  • White & Case (New York)
  • White & Case (Washington)
  • White & Case (New York)

Quotation

Jack E. Pace, Kristen O'Shaughnessy, Robert Milne, Peter J. Carney, Michael Gallagher, Mark J. Gidley, Kevin Adam, The US Congress proposes a package of bills on drug pricing, including changes to the treatment of reverse payments, product hopping, sham petitions, and patent dancing, 21 April 2021, e-Competitions April 2021, Art. N° 101094

Visites 144

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues